Karyopharm Therapeutics Inc.
KPTI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KPTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing and marketing XPOVIO (selinexor) for cancer indications, currently facing significant financial challenges with substantial doubt about its ability to continue as a going concern beyond September 2026.
Key risk: Going concern uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$42.4M
Cash Runway
9.3 moLead Asset
eltanexor (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 14 clinical trials · 4 catalysts · 1 FDA decision for Karyopharm Therapeutics Inc..
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing and marketing XPOVIO (selinexor) for cancer indications, currently facing significant financial challenges with substantial doubt about its ability to continue as a going concern beyond September 2026.
- Karyopharm is a commercial-stage company primarily marketing XPOVIO (selinexor) in approved indications, with a pipeline including myelofibrosis, endometrial cancer, and multiple myeloma [sec · filed 2026-04-13].
- As of June 30, 2026, the company reported cash & equivalents of $55.3M, total revenue of $33.4M, net loss of -$67.0M, and negative shareholders' equity of -$238.9M [sec].
- The company has substantial doubt about its ability to continue as a going concern, with existing liquidity expected to fund operations only into September 2026 [sec_mda · as of 2026-08-13].
- Karyopharm is actively exploring financing transactions and strategic alternatives, including a potential sNDA submission for selinexor in myelofibrosis, but there is no assurance of success [sec · filed 2026-07-31].
What works
- Karyopharm has a commercially approved product, XPOVIO, generating revenue in the multiple myeloma market [sec · filed 2026-04-13].
- The company is advancing a late-stage pipeline, including a lead program in myelofibrosis, which could address high unmet need if approved [sec · filed 2025-04-14].
- Karyopharm has engaged financial advisors (Centerview Partners) to explore strategic alternatives to extend cash runway and maximize stakeholder value [sec_mda · as of 2026-08-13].
What to weigh
- Karyopharm has incurred recurring losses since inception, with a net loss of $67.0M in the first half of 2026 and negative shareholders' equity [sec · filed 2026-07-31].
- There is substantial doubt about the company's ability to continue as a going concern, with cash runway only into September 2026 and a $15.8M debt payment due on September 10, 2026 [sec_mda · as of 2026-08-13].
- The FDA has requested additional data for the selinexor sNDA in myelofibrosis, creating uncertainty in the regulatory timeline [sec · filed 2026-07-31].
- The company faces risks in commercial adoption of XPOVIO and successful completion of clinical trials for pipeline candidates [sec · filed 2026-07-31].
From the filings
Quoted directly from source documents.
Substantial doubt about going concern within one year
“we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”
SEC MD&A · May 14, 2026
Cash runway expected only into September 2026
“We expect that our existing liquidity, including cash, cash equivalents, and investments as well as cash flow from net product revenue and license and other revenue, will enable us to fund our current operating plans into September 2026.”
SEC MD&A · August 13, 2026
FDA requires further discussion on sNDA data
“the Company received additional correspondence from the FDA indicating that the FDA requires further discussion on the data to be used to support the sNDA and convert potential accelerated approval to traditional approval.”
SEC filings · July 31, 2026
Company exploring financing and strategic alternatives
“The Company, with the assistance of its advisors, including its financial advisor Centerview Partners, is exploring potential financing transactions to extend its cash runway along with strategic alternatives”
SEC filings · July 31, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline · rituximab-gemcitabine-dexamethasone-platinum — Phase 3 Topline: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) Wi — Topline data from the Phase 2/3 study of selinexor in combination with R-GDP will be read out, potentially impacting the pipeline.
- 2028-01-01 · Phase3_Topline · selinexor — Phase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenan — Topline data from a Phase 3 maintenance trial of selinexor will be available, informing its potential in multiple myeloma.
- 2028-03-01 · Phase3_Topline · ruxolitinib — Phase 3 Topline: A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Exp — Topline data from the Phase 1/3 study of selinexor in combination with ruxolitinib in myelofibrosis will be released.
- 2035-08-14 · Patent_Expiry · XPOVIO — Patent/Exclusivity Expiry: XPOVIO — Patent exclusivity for XPOVIO is set to expire, which could open the market to generic competition.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern beyond September 2026 without additional funding [sec_mda · as of 2026-08-13].
- Cash runway limited — Existing liquidity expected to fund operations only into September 2026, with a $15.8M debt payment due on September 10, 2026 [sec_mda · as of 2026-08-13].
- Regulatory delay for selinexor — FDA requires further discussion on data for selinexor sNDA in myelofibrosis, delaying potential approval [sec · filed 2026-07-31].
- Recurring operating losses — Company has incurred significant losses since inception, with a net loss of $49.3M in the first half of 2026 [sec_mda · as of 2026-08-13].
What to watch
- Ability to secure financing or strategic alternative to extend cash runway beyond September 2026 [sec_mda · as of 2026-08-13].
- FDA feedback and potential sNDA submission for selinexor in myelofibrosis, expected in August 2026 [sec · filed 2026-07-31].
- Upcoming Phase 3 topline data for selinexor in combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP) expected December 2026 [catalyst].
- Debt payment of $15.8M due on September 10, 2026, and its impact on liquidity [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Karyopharm Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Karyopharm Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.3 months
OCF -$25M · Net income -$67M
Lead: Approved
2 candidates
4 upcoming, next in ~93d
0 buys · 8 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
80
Total value held
$119.7M
| Holder | Shares | Value |
|---|---|---|
| commodore capital lp | 1,950,000 | $10.9M |
| ra capital management, l.p. | 1,917,354 | $10.7M |
| adage capital partners gp, l.l.c. | 1,806,322 | $10.1M |
| vanguard capital management llc | 1,479,490 | $8.2M |
| susquehanna international group, llp | 1,315,038 | $7.3M |
| caption management, llc | 1,181,900 | $6.6M |
| avidity partners management lp | 927,482 | $6.4M |
| goldman sachs group inc | 947,579 | $5.3M |
| boothbay fund management, llc | 750,410 | $4.2M |
| squadron capital management llc | 750,000 | $4.2M |
Showing top 10 of 80 institutional holders of Karyopharm Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 25.5%
- Days to cover
- 3.4
- Shares short
- 5,718,250
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KPTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing and marketing XPOVIO (selinexor) for cancer indications, currently facing significant financial challenges with substantial doubt about its ability to continue as a going concern beyond September 2026.
What is Karyopharm Therapeutics Inc.'s lead drug candidate?
Karyopharm Therapeutics Inc.'s most advanced tracked candidate is eltanexor (Phase 3) for Myeloproliferative neoplasms and TP53 wild-type tumors.
What is Karyopharm Therapeutics Inc.'s next catalyst?
Karyopharm Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) Wi" — expected December 1, 2026.
Who is the CEO of Karyopharm Therapeutics Inc.?
Mr. Richard A. Paulson M.B.A. is the chief executive officer of Karyopharm Therapeutics Inc. (KPTI).
Where is Karyopharm Therapeutics Inc. headquartered?
Karyopharm Therapeutics Inc. (KPTI) is headquartered in Newton, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.